Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
For full access to this article login to GEN Select now.
Refining Protein Drug Formulation
Strategies for Overcoming Critical Issues Like Aggregation and Stability
- The protein therapeutics market totaled $63 billion in 2007 ($39 billion in the U.S. alone) and is expected to reach $87 billion by 2010, according to a report by Kalorama Information—“Protein Therapeutics: The Science and Business of a Growing Sector.” Although the protein therapeutics market is significantly smaller than ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.